82 related articles for article (PubMed ID: 37596147)
21. Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer.
Mearini E; Poli G; Cochetti G; Boni A; Egidi MG; Brancorsini S
Onco Targets Ther; 2017; 10():2665-2673. PubMed ID: 28579804
[TBL] [Abstract][Full Text] [Related]
22. LncRNA LINC00466 Promotes the Progression of Breast Cancer via miR-4731-5p/EPHA2 Pathway.
Han X; Shi F; Guo S; Li Y; Wang H; Song C; Wu S
Curr Pharm Biotechnol; 2024 May; ():. PubMed ID: 38726776
[TBL] [Abstract][Full Text] [Related]
23. Mining of potential microRNAs with clinical correlation - regulation of syndecan-1 expression by miR-122-5p altered mobility of breast cancer cells and possible correlation with liver injury.
Uen Y; Wang JW; Wang C; Jhang Y; Chung JY; Tseng T; Sheu M; Lee S
Oncotarget; 2018 Jun; 9(46):28165-28175. PubMed ID: 29963269
[TBL] [Abstract][Full Text] [Related]
24. Association of deletion polymorphism rs10573247 in the HMGA2 gene with the risk of breast cancer: bioinformatic and experimental analyses.
Najibi K; Moghanibashi M; Naeimi S
World J Surg Oncol; 2024 May; 22(1):142. PubMed ID: 38802807
[TBL] [Abstract][Full Text] [Related]
25. Study of MicroRNA Cluster Located on Chromosome X in Serum and Breast Cancer Tissue.
Rasool AA; Haghi M; Hosseinpour Feizi MA
Biochem Genet; 2024 Apr; 62(2):1115-1135. PubMed ID: 37544000
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability.
Uhlmann EJ; Mackel CE; Deforzh E; Rabinovsky R; Brastianos PK; Varma H; Vega RA; Krichevsky AM
J Neurooncol; 2023 Mar; 162(1):109-118. PubMed ID: 36809604
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA Targets PAP1 to Mediate Melanization in
Zhang Z; Jin F; Huang J; Mandal S; Zeng L; Zafar J; Xu X
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256210
[TBL] [Abstract][Full Text] [Related]
28. Pseudogene OCT4-pg5 upregulates OCT4B expression to promote bladder cancer progression by competing with miR-145-5p.
Zhou W; Yang Y; Wang W; Yang C; Cao Z; Lin X; Zhang H; Xiao Y; Zhang X
Cell Cycle; 2024 Jun; ():1-17. PubMed ID: 38842275
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-190b Targets RFWD3 in Estrogen Receptor-Positive Breast Cancer.
Frick EA; Kristjansdottir K; Ragnarsdottir S; Vilhjalmsson AI; Bustos MR; Vidarsdottir L; Gudjonsson T; Sigurdsson S
Breast Cancer (Auckl); 2024; 18():11782234241234771. PubMed ID: 38504674
[TBL] [Abstract][Full Text] [Related]
30. SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor β.
Parija M; Prakash S; Krishna BM; Dash S; Mishra SK
Breast Cancer; 2024 May; 31(3):440-455. PubMed ID: 38421553
[TBL] [Abstract][Full Text] [Related]
31. Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.
Campos-Parra AD; Mitznahuatl GC; Pedroza-Torres A; Romo RV; Reyes FIP; López-Urrutia E; Pérez-Plasencia C
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28574440
[TBL] [Abstract][Full Text] [Related]
32. MiR-218-5p/EGFR Signaling in Arsenic-Induced Carcinogenesis.
Islam R; Zhao L; Zhang X; Liu LZ
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831545
[TBL] [Abstract][Full Text] [Related]
33. Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors.
Katsaraki K; Kontos CK; Ardavanis-Loukeris G; Tzovaras AA; Sideris DC; Scorilas A
Clin Transl Oncol; 2024 May; 26(5):1256-1267. PubMed ID: 38038871
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic significance of long noncoding RNAs in estrogen receptor-positive breast cancer.
Alzahrani AA; Saleh RO; Latypova A; Bokov DO; Kareem AH; Talib HA; Hameed NM; Pramanik A; Alawadi A; Alsalamy A
Cell Biochem Funct; 2024 Apr; 42(3):e3993. PubMed ID: 38532685
[TBL] [Abstract][Full Text] [Related]
35. The role of miRNAs as biomarkers in breast cancer.
Baylie T; Kasaw M; Getinet M; Getie G; Jemal M; Nigatu A; Ahmed H; Bogale M
Front Oncol; 2024; 14():1374821. PubMed ID: 38812786
[TBL] [Abstract][Full Text] [Related]
36. [Estrogen, estrogen receptor and miR-21 in adenomyosis: their pathogenic roles and regulatory interactions].
Zeng Y; Jia J; Lu J; Zeng C; Geng H; Chen Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Apr; 44(4):627-635. PubMed ID: 38708494
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer Effects of a Chitosan Based Nanoformulation Expressing miR-340 on 4T1 Breast Cancer Cells.
Kashefi S; Mohammadi-Yeganeh S; Ghorbani-Bidkorpeh F; Shabani M; Koochaki A; Safarzadeh M; Hoseini MHM
J Pharm Sci; 2024 Feb; 113(2):445-454. PubMed ID: 37806438
[TBL] [Abstract][Full Text] [Related]
38. miR-317-3p and miR-283-5p Play a Crucial Role in Regulating the Resistance to Indoxacarb in
Wu M; Lv H; Guo Z; Li S; Tang J; Li J; You H; Ma K
J Agric Food Chem; 2024 Apr; 72(13):6889-6899. PubMed ID: 38512131
[No Abstract] [Full Text] [Related]
39. Targeting estrogen mediated CYP4F2/CYP4F11-20-HETE metabolic disorder decelerates tumorigenesis in ER+ breast cancer.
Yang J; Li Y; Han X; Li T; Li D; Liu Q; Yan L; Li F; Pei X; Feng Y; Lin Z; Fu Z; Wang C; Sun Q; Li C
Biochem Biophys Rep; 2024 Jul; 38():101706. PubMed ID: 38646426
[TBL] [Abstract][Full Text] [Related]
40. MiRNA-516a promotes bladder cancer metastasis by inhibiting MMP9 protein degradation via the AKT/FOXO3A/SMURF1 axis.
Chang Y; Jin H; Li H; Ma J; Zheng Z; Sun B; Lyu Y; Lin M; Zhao H; Shen L; Zhang R; Wu S; Lin W; Lu Y; Xie Q; Zhang G; Huang X; Huang H
Clin Transl Med; 2020 Dec; 10(8):e263. PubMed ID: 33377649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
